A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder

International Journal of Neuropsychopharmacology

Volumn 9, Issue 1, 2006, Pages 83-88

  Masui, Takuya ^a   Hashimoto, Ryota ^b   Kusumi, Ichiro ^a   Suzuki, Katsuji ^a   Tanaka, Teruaki ^a   Nakagawa, Shin ^a   Kunugi, Hiroshi ^b   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Bipolar disorder; Lithium; SNP (single nucleotide polymorphism); XBP1

Indexed keywords

BINDING PROTEIN; LITHIUM; MOOD STABILIZER; UNCLASSIFIED DRUG; VALPROIC ACID; X BOX BINDING PROTEIN 1;

ADULT; ALLELE; ARTICLE; BIPOLAR DISORDER; CELL CULTURE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; ENDOPLASMIC RETICULUM; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPOTHESIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; TREATMENT OUTCOME;

ADULT; ALLELES; ANTIMANIC AGENTS; BIPOLAR DISORDER; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; JAPAN; LITHIUM CARBONATE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 30344450371     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705005523     Document Type: Article

References (21)

1. Abou-Saleh MT (1987). How long should drug therapy for depression be maintained? American Journal of Psychiatry 144, 1247-1248.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
3. APA (American Psychiatric Association) (2002). Practical guideline for the treatment of patients with bipolar disorder (Revision). American Journal of Psychiatry 159, 1-50.
4. Badner JA, Gershon ES (2002). Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Molecular Psychiatry 7, 405-411.
5. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK (2000). Enhancement of hippocampal neurogenesis by lithium. Journal of Neurochemistry 75, 1729-1734.
6. Chen W, Duan S, Zhou J, Sun Y, Zheng Y, Gu N, Feng G, He L (2004). A case-control study provides evidence of association for a functional polymorphism -197C/G in XBP1 to schizophrenia and suggests a sex-dependent effect. Biochemical and Biophysical Research Communications 319, 866-870.
7. Cichon S, Buervenich S, Kirov G, Akula N, Dimitrova A, Green E, Schumacher J, Klopp N, Becker T, Ohlraun S, et al. (2004) Lack of support for a genetic association of the XBP1 promoter polymorphism with bipolar disorder in probands of European origin. Nature Genetics 36, 783-785.
8. Gelenberg AJ, Pies R (2003) Matching the bipolar patient and the mood stabilizer. Annals of Clinical Psychiatry 15, 203-216.
9. Hallcher LM, Sherman WR (1980). The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. Journal of Biological Chemistry 255, 10896-10901.
10. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM (2002a). Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. Journal of Neurochemistry 80, 589-597.
11. Hashimoto R, Senatorov V, Kanai H, Leeds P, Chuang DM (2003). Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience 117, 55-61.
12. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM (2002b). Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43, 1173-1179.
13. Hashimoto R, Yoshida M, Ozaki N, Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Tatsumi M, Kamijima K, Kunugi H (2004). Association analysis of the -308G > A promoter polymorphism of the tumor necrosis factor alpha (TNF-α) gene in Japanese patients with schizophrenia. Journal of Neural Transmission 111, 217-221.
14. Hiroi T, Wei H, Hough C, Leeds P, Chuang DM (2005). Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: role of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics Journal 5, 102-111.
15. Hou SJ, Yen FC, Cheng CY, Tsai SJ, Hong CJ (2004). X-box binding protein 1 (XBP1) C -116G polymorphisms in bipolar disorders and age of onset. Neuroscience Letters 367, 232-234.
16. Ikeda A, Kato T (2003). Biological predictors of lithium response in bipolar disorder. Psychiatry and Clinical Neurosciences 57, 243-250.
17. Kakiuchi C, Ishiwata M, Umekage T, Tochigi M, Kohda K, Sasaki T, Kato T (2004). Association of the XBP1 -116C/G polymorphism with schizophrenia in the Japanese population. Psychiatry and Clinical Neurosciences 58, 438-440.
18. Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, Kusumi I, Tsujita T, Okazaki Y, Nanko S, Kunugi H, Sasaki T, Kato T (2003). Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nature Genetics 35, 171-175.
19. Kato T, Inubushi T, Kato N (2000). Prediction of lithium response by 31P-MRS in bipolar disorder. International Journal of Neuropsychopharmacology 3, 83-85.
20. Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences USA 93, 8455-8459.
21. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD (2002). Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 26, 530-536.